Form 4: Zevra Director Alvin Shih Buys 20,000 Shares

Zevra Therapeutics Director Alvin Shih acquired 20,000 shares of common stock at a weighted average price of $7.89, signaling increased insider ownership.

Summary

• Alvin Shih, a Director of ZEVRA THERAPEUTICS, INC. (ZVRA), purchased 20,000 shares of the company's common stock.
• The transaction occurred on September 12, 2025, at a weighted average price of $7.89 per share.
• The purchase price ranged from $7.85 to $7.90 per share.
• The acquisition was made directly by Mr. Shih.
• The transaction was executed pursuant to a Rule 10b5-1(c) trading plan.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a director's significant purchase of company stock, indicating strong insider confidence in the company's future.

Positives

• Director Alvin Shih's acquisition of 20,000 shares demonstrates a direct investment and increased confidence in Zevra Therapeutics' future prospects.
• The purchase was made at a weighted average price of $7.89 per share, indicating a belief in the current valuation.
• The transaction was conducted under a Rule 10b5-1(c) plan, suggesting a pre-planned investment strategy rather than a reactive one.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the insider purchase implicitly signals management's positive outlook on the company's future performance.

Management Comments

• Director Alvin Shih's decision to acquire 20,000 shares of Zevra Therapeutics common stock reflects a strong vote of confidence in the company's strategic direction and value proposition.

Industry Context

Insider buying, particularly by a director, is often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or poised for growth. This action aligns with a broader trend where insider sentiment can influence investor perception and potentially attract further investment.

Corporate Governance

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of the company's future performance and value, potentially increasing investor confidence.
• Employees might perceive this as a sign of stability and positive outlook from leadership.

Key Dates

Recommendation

The direct purchase of 20,000 shares by a company director, Alvin Shih, at market prices is a strong signal of insider confidence. This action, especially when executed under a Rule 10b5-1 plan, suggests a belief in the company's intrinsic value and future growth prospects. Such insider buying often precedes positive company developments and can be a compelling reason for investors to consider a 'buy' recommendation, as it aligns management's interests directly with those of shareholders.

Keywords

ZEVRA THERAPEUTICS, ZVRA, Alvin Shih, Director, Insider Trading, Stock Purchase, Common Stock, Form 4, Rule 10b5-1